Abstract:Herein, we communicate our recent medicinal chemistry efforts which have culminated in a series of PI3K delta/gamma dual inhibitors structurally featuring a seven-membered spirocyclic spacer. Compound 26, the most potent one among them, exhibited superior PI3K delta inhibitory activity (IC50 = 1.0 nM) to that of the approved PI3K delta inhibitor Idelalisib. Besides, it exerted remarkable anti-proliferative efficacy against human malignant B-cell line SU-DHL-6 with GI(50) value of 33 nM. The biochemical assay against the other three class I PI3K isoforms identified compound 26 as a potent PI3K delta/gamma dual inhibitor with considerable selectivity over PI3K alpha and PI3K beta. In SU-DHL-6 cells, a dramatic down-regulation of PI3K signaling was observed following compound 26-treatment at the concentration as low as 10 nM. Inspiringly, the pharmacokinetic (PK) study in Sprague-Dawley (SD) rats revealed it was orally available with a favorable bioavailability (F = 87.5%). Overall, compound 26, a promising PI3K delta/gamma dual inhibitor, has the potential to emerge as a clinical candidate for the treatment of leukocyte-mediated malignancies after extensive functional investigation. (c) 2020 Elsevier Masson SAS. All rights reserved.

Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Discovery and SAR of Thiazolidine-2,4-dione Analogues As Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitors Via Hierarchical Virtual Screening

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Discovery of 2-Methyl-2-(4-(2-methyl-8-(1 H -pyrrolo[2,3- b ]pyridin-6-yl)-1 H -naphtho[1,2- d ]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo

Discovery of 3-(5 '-Substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-i Ndazoles As Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives As PI3K Inhibitors with Potent Activity.

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R

Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors

Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor.

Discovery of Ureido-Substituted 4-Phenylthiazole Derivatives as IGF1R Inhibitors with Potent Antiproliferative Properties

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors

Discovery and development of quinazoline compounds as irreversible pan-fibroblast growth factor receptor inhibitors with potent antitumor activities

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5 '-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (Pki-587), A Highly Efficacious Dual Inhibitor